Keywords
Last Name
Institution

DONALD BERRY

TitleProfessor
InstitutionMD Anderson
DepartmentBiostatistics
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ. Neoadjuvant as Future for Drug Development in Breast Cancer-Response. Clin Cancer Res. 2016 Jan 1; 22(1):269. PMID: 26728411.
      View in: PubMed
    2. Berry DA. Emerging innovations in clinical trial design. Clin Pharmacol Ther. 2016 Jan; 99(1):82-91. PMID: 26561040.
      View in: PubMed
    3. Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC. CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol. 2015 Nov; 17 Suppl 6:vi1-26. PMID: 26403167.
      View in: PubMed
    4. Berry DA. Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer. Clin Cancer Res. 2016 Jan 1; 22(1):3-5. PMID: 26510857.
      View in: PubMed
    5. Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH. Advancing Clinical Trials to Streamline Drug Development. Clin Cancer Res. 2015 Oct 15; 21(20):4527-35. PMID: 26473188.
      View in: PubMed
    6. Berry DA, Hudis CA. Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval. JAMA Oncol. 2015 Oct; 1(7):875-6. PMID: 26181139.
      View in: PubMed
    7. Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, Somlo G, Hudis C, Winer E, Ollila DW. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015 Sep; 262(3):434-9; discussion 438-9. PMID: 26222764.
      View in: PubMed
    8. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol. 2015 Nov 1; 33(31):3583-90. PMID: 26304898.
      View in: PubMed
    9. Lenz RA, Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, Sadowsky CH, Abi-Saab WM, Saltarelli MD. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord. 2015 Jul-Sep; 29(3):192-9. PMID: 25973909.
      View in: PubMed
    10. Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015 Sep; 107(9). PMID: 26113580.
      View in: PubMed
    11. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015 Jun; 16(6):630-7. PMID: 25981812.
      View in: PubMed
    12. Kang BP, Slosberg E, Snodgrass S, Lebedinsky C, Berry DA, Corless CL, Stein S, Salvado A. The Signature Program: Bringing the Protocol to the Patient. Clin Pharmacol Ther. 2015 Aug; 98(2):124-6. PMID: 25810246.
      View in: PubMed
    13. Legocki LJ, Meurer WJ, Frederiksen S, Lewis RJ, Durkalski VL, Berry DA, Barsan WG, Fetters MD. Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis. BMC Med Ethics. 2015; 16:27. PMID: 25933921.
      View in: PubMed
    14. Berry DA. The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol. 2015 May; 9(5):951-9. PMID: 25888066.
      View in: PubMed
    15. Perry D, Sperling R, Katz R, Berry D, Dilts D, Hanna D, Salloway S, Trojanowski JQ, Bountra C, Krams M, Luthman J, Potkin S, Gribkoff V, Temple R, Wang Y, Carrillo MC, Stephenson D, Snyder H, Liu E, Ware T, McKew J, Fields FO, Bain LJ, Bens C. Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev Neurother. 2015 Mar; 15(3):327-33. PMID: 25708309.
      View in: PubMed
    16. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 1; 21(13):2911-5. PMID: 25712686.
      View in: PubMed
    17. Berry DA. Commentary on Hey and Kimmelman. Clin Trials. 2015 Apr; 12(2):107-9. PMID: 25649111.
      View in: PubMed
    18. Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro Oncol. 2015 Aug; 17(8):1106-13. PMID: 25568226.
      View in: PubMed
    19. Shulman LN, Berry DA, Cirrincione CT, Hudis CA, Winer EP. Reply to V. Amoroso et al. J Clin Oncol. 2015 Jan 20; 33(3):291. PMID: 25512457.
      View in: PubMed
    20. Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11):1629-49. PMID: 25361808.
      View in: PubMed
    21. Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014 Nov; 106(11). PMID: 25255803.
      View in: PubMed
    22. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. PMID: 25165194.
      View in: PubMed
    23. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1; 33(1):13-21. PMID: 25092775.
      View in: PubMed
    24. Berry DA. CYP2D6 genotype and adjuvant tamoxifen. Clin Pharmacol Ther. 2014 Aug; 96(2):138-40. PMID: 25056391.
      View in: PubMed
    25. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36. PMID: 24987059.
      View in: PubMed
    26. Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 1; 32(22):2311-7. PMID: 24934787.
      View in: PubMed
    27. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014 Jul 29; 111(3):628-36. PMID: 24921909.
      View in: PubMed
    28. Berry DA. Failure of researchers, reviewers, editors, and the media to understand flaws in cancer screening studies: application to an article in Cancer. Cancer. 2014 Sep 15; 120(18):2784-91. PMID: 24925345.
      View in: PubMed
    29. Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014 Jun; 106(6):dju092. PMID: 24872543.
      View in: PubMed
    30. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014 May; 15(6):e234-42. PMID: 24807866.
      View in: PubMed
    31. Berry DA. Response. J Natl Cancer Inst. 2014 May; 106(5). PMID: 24700800.
      View in: PubMed
    32. Broglio KR, Stivers DN, Berry DA. Predicting clinical trial results based on announcements of interim analyses. Trials. 2014; 15:73. PMID: 24607270; PMCID: PMC3973959.
    33. Berry DA. Response. J Natl Cancer Inst. 2014 Feb; 106(2):djt380. PMID: 24408654.
      View in: PubMed
    34. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014; 36:114-36. PMID: 24375928; PMCID: PMC3873844.
    35. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. J Clin Oncol. 2013 Dec 20; 31(36):4571-3. PMID: 24190113.
      View in: PubMed
    36. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114. PMID: 24205370.
      View in: PubMed
    37. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9. PMID: 24210755; PMCID: PMC3946849.
    38. Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials. Clin Trials. 2013 Oct; 10(5):720-34. PMID: 23983156.
      View in: PubMed
    39. Berry D. CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst. 2013 Sep 4; 105(17):1267-9. PMID: 23958737.
      View in: PubMed
    40. Berry DA. Breast cancer screening: controversy of impact. Breast. 2013 Aug; 22 Suppl 2:S73-6. PMID: 24074796; PMCID: PMC4192714.
    41. Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8. PMID: 23857706; PMCID: PMC3714161.
    42. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 1; 31(19):2382-7. PMID: 23690420; PMCID: PMC3691356.
    43. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, Berry DA. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013 Jun; 24(6):1207-22. PMID: 23563998; PMCID: PMC4161278.
    44. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 1; 19(11):2817-23. PMID: 23470967; PMCID: PMC4096560.
    45. Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):457-66. PMID: 23423445; PMCID: PMC3608881.
    46. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      View in: PubMed
    47. Geiger MJ, Skrivanek Z, Gaydos B, Chien J, Berry S, Berry D. An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics. J Diabetes Sci Technol. 2012; 6(6):1319-27. PMID: 23294776.
      View in: PubMed
    48. Skrivanek Z, Berry S, Berry D, Chien J, Geiger MJ, Anderson JH, Gaydos B. Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations. J Diabetes Sci Technol. 2012; 6(6):1305-18. PMID: 23294775; PMCID: PMC3570870.
    49. Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res. 2012 Nov 15; 18(22):6356-63. PMID: 23014530.
      View in: PubMed
    50. Younes A, Berry DA. From drug discovery to biomarker-driven clinical trials in lymphoma. Nat Rev Clin Oncol. 2012 Nov; 9(11):643-53. PMID: 22965151.
      View in: PubMed
    51. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. PMID: 22966018.
      View in: PubMed
    52. Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(1):35-43. PMID: 22961065.
      View in: PubMed
    53. Berry D. Multiplicities in cancer research: ubiquitous and necessary evils. J Natl Cancer Inst. 2012 Aug 8; 104(15):1124-32. PMID: 22859849.
      View in: PubMed
    54. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20; 30(33):4071-6. PMID: 22826271; PMCID: PMC3494835.
    55. Collins SP, Lindsell CJ, Pang PS, Storrow AB, Peacock WF, Levy P, Rahbar MH, Del Junco D, Gheorghiade M, Berry DA. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am Heart J. 2012 Aug; 164(2):138-45. PMID: 22877798; PMCID: PMC3417230.
    56. O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJ. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol. 2012 Sep; 158(5):581-8. PMID: 22702906; PMCID: PMC4191720.
    57. Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? JAMA. 2012 Jun 13; 307(22):2377-8. PMID: 22692168.
      View in: PubMed
    58. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012 Jun 13; 307(22):2418-29. PMID: 22610500; PMCID: PMC3709596.
    59. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. PMID: 22649152.
      View in: PubMed
    60. Meurer WJ, Lewis RJ, Tagle D, Fetters MD, Legocki L, Berry S, Connor J, Durkalski V, Elm J, Zhao W, Frederiksen S, Silbergleit R, Palesch Y, Berry DA, Barsan WG. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012 Oct; 60(4):451-7. PMID: 22424650; PMCID: PMC3557826.
    61. Ellenberg S, Luce B, Fleming T, Siegel J, Strom B, Hernán M, Temple R, Sackett D, Bourguignon C, Bekelman J, Berry D, Rotelli M, Judkins D, Schwartz S, Goodman S. Panel discussion 2. Clin Trials. 2012 Feb; 9(1):66-79. PMID: 22334467.
      View in: PubMed
    62. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res. 2012 Feb 1; 18(3):638-44. PMID: 22298897.
      View in: PubMed
    63. Ji Y, Feng L, Liu P, Shpall EJ, Kebriaei P, Champlin R, Berry D, Cooper LJ. Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. J Biopharm Stat. 2012; 22(6):1206-19. PMID: 23075018; PMCID: PMC3501341.
    64. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. PMID: 22198468; PMCID: PMC3332388.
    65. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2012 Apr; 9(4):199-207. PMID: 22064459.
      View in: PubMed
    66. Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, Feuer EJ. Modeling the impact of population screening on breast cancer mortality in the United States. Breast. 2011 Oct; 20 Suppl 3:S75-81. PMID: 22015298; PMCID: PMC3457919.
    67. Berry DA. Bayesian approaches for comparative effectiveness research. Clin Trials. 2012 Feb; 9(1):37-47. PMID: 21878446; PMCID: PMC4314707.
    68. Berry DA. Next generation clinical trials. Clin Adv Hematol Oncol. 2011 Aug; 9(8):601-3. PMID: 22236987.
      View in: PubMed
    69. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr; 132(3):871-9. PMID: 21796368.
      View in: PubMed
    70. Berry DA. Computer-assisted detection and screening mammography: where's the beef? J Natl Cancer Inst. 2011 Aug 3; 103(15):1139-41. PMID: 21795666.
      View in: PubMed
    71. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M, Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3224-31. PMID: 21768454.
      View in: PubMed
    72. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3214-23. PMID: 21768471.
      View in: PubMed
    73. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 1; 17(15):5170-8. PMID: 21693655; PMCID: PMC3149770.
    74. Connor JT, Lewis RJ, Berry DA, Berry SM. FDA recalls not as alarming as they seem. Arch Intern Med. 2011 Jun 13; 171(11):1044-5; author reply 1045-6. PMID: 21670380.
      View in: PubMed
    75. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011 Jul 10; 29(20):2787-94. PMID: 21632504.
      View in: PubMed
    76. Berry SM, Broglio KR, Berry DA. Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis. Cancer Invest. 2011 May; 29(4):293-9. PMID: 21469978.
      View in: PubMed
    77. Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol. 2011 Jun 1; 29(16):2282-90. PMID: 21519016.
      View in: PubMed
    78. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol. 2011 Feb 20; 29(6):606-9. PMID: 21172875.
      View in: PubMed
    79. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 2011 Jan 20; 29(3):294-302. PMID: 21149654; PMCID: PMC3056464.
    80. Baum M, Thornton H, Gøtzsche PC, Bewley S, Jørgensen KJ, Barratt A, Ross N, Woloshin S, Schwartz L, Musiello T, Blennerhassett M, Napoli M, Baines CJ, Vaidya JS, Williams N, Havercroft D, Zahl PH, Retsky M, Kaplan RM, Dixon-Woods M, Berry DA, Isaacson K, Brahams D, Pryke M, Tindall G, Bender DA, Marshall T. Breast cancer awareness month. Still awaiting screening facts. BMJ. 2010; 341:c6152. PMID: 21045038.
      View in: PubMed
    81. Berry DA. The hazards of endpoints. J Natl Cancer Inst. 2010 Sep 22; 102(18):1376-7. PMID: 20826734.
      View in: PubMed
    82. Goodman S, Berry D, Wittes J. Bias and trials stopped early for benefit. JAMA. 2010 Jul 14; 304(2):157; author reply 158-9. PMID: 20628126.
      View in: PubMed
    83. Berry SM, Ishak KJ, Luce BR, Berry DA. Bayesian meta-analyses for comparative effectiveness and informing coverage decisions. Med Care. 2010 Jun; 48(6 Suppl):S137-44. PMID: 20473185.
      View in: PubMed
    84. Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010 May 10; 28(14):2418-22. PMID: 20368559; PMCID: PMC2881723.
    85. Berry SM, Spinelli W, Littman GS, Liang JZ, Fardipour P, Berry DA, Lewis RJ, Krams M. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clin Trials. 2010 Apr; 7(2):121-35. PMID: 20338905.
      View in: PubMed
    86. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9. PMID: 20215557; PMCID: PMC2840069.
    87. Sanchez de Toledo J, Gunawardena S, Munoz R, Orr R, Berry D, Sonderman S, Krallman S, Shiderly D, Wang L, Wearden P, Morell VO, Chrysostomou C. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit? Cardiol Young. 2010 Apr; 20(2):138-43. PMID: 20199704.
      View in: PubMed
    88. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010 Jan 27; 303(4):333-40. PMID: 20103757.
      View in: PubMed
    89. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010 Feb 16; 102(4):651-7. PMID: 20104228; PMCID: PMC2837571.
    90. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010 Jan; 51(1):73-8. PMID: 20017599; PMCID: PMC2876330.
    91. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 1; 28(4):605-13. PMID: 20038729; PMCID: PMC2815995.
    92. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009 Nov 17; 151(10):738-47. PMID: 19920274.
      View in: PubMed
    93. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009 Dec 2; 101(23):1642-9. PMID: 19903805; PMCID: PMC4137232.
    94. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 1; 27(34):5700-6. PMID: 19884543; PMCID: PMC2792998.
    95. Chrysostomou C, Sanchez De Toledo J, Avolio T, Motoa MV, Berry D, Morell VO, Orr R, Munoz R. Dexmedetomidine use in a pediatric cardiac intensive care unit: can we use it in infants after cardiac surgery? Pediatr Crit Care Med. 2009 Nov; 10(6):654-60. PMID: 19295456.
      View in: PubMed
    96. Berry DA. Adjuvant chemotherapy for breast cancer in older women. Womens Health (Lond Engl). 2009 Sep; 5(5):453-7. PMID: 19702442.
      View in: PubMed
    97. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 6:S1-S21; quiz S22-3. PMID: 19755043.
      View in: PubMed
    98. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials. 2009 Jun; 6(3):205-16. PMID: 19528130.
      View in: PubMed
    99. Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med. 2009 May 30; 28(12):1680-9. PMID: 19326367.
      View in: PubMed
    100. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20; 27(21):3430-6. PMID: 19470942.
      View in: PubMed
    101. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65. PMID: 19439741; PMCID: PMC3082436.
    102. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul; 86(1):97-100. PMID: 19440188.
      View in: PubMed
    103. Berry D, Wathen JK, Newell M. Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin Trials. 2009 Feb; 6(1):28-41. PMID: 19254931.
      View in: PubMed
    104. Berry DA, Baines CJ, Baum M, Dickersin K, Fletcher SW, Gøtzsche PC, Jørgensen KJ, Junod B, Maehlen J, Schwartz LM, Welch HG, Woloshin S, Thornton H, Zahl PH. Flawed inferences about screening mammography's benefit based on observational data. J Clin Oncol. 2009 Feb 1; 27(4):639-40; author reply 641-2. PMID: 19075270.
      View in: PubMed
    105. Chrysostomou C, Beerman L, Shiderly D, Berry D, Morell VO, Munoz R. Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study. Anesth Analg. 2008 Nov; 107(5):1514-22. PMID: 18931208.
      View in: PubMed
    106. Berry DA. The science of doping. Nature. 2008 Aug 7; 454(7205):692-3. PMID: 18685682.
      View in: PubMed
    107. Julian TB, Blumencranz P, Deck K, Whitworth P, Berry DA, Berry SM, Rosenberg A, Chagpar AB, Reintgen D, Beitsch P, Simmons R, Saha S, Mamounas EP, Giuliano A. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008 Jul 10; 26(20):3338-45. PMID: 18612150.
      View in: PubMed
    108. Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 1; 26(16):2659-65. PMID: 18509177.
      View in: PubMed
    109. Berry DA. The screening mammography paradox: better when found, perhaps better not to find. Br J Cancer. 2008 Jun 3; 98(11):1729-30. PMID: 18506172; PMCID: PMC2410106.
    110. Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1096-103. PMID: 18483331; PMCID: PMC2701362.
    111. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72. PMID: 18390970.
      View in: PubMed
    112. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 1; 26(10):1642-9. PMID: 18375893.
      View in: PubMed
    113. Kimmick GG, Cirrincione C, Duggan DB, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson IC, Hudis C, Winer E. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009 Feb; 113(3):479-90. PMID: 18306034.
      View in: PubMed
    114. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol. 2008 Feb 10; 26(5):806-13. PMID: 18258990.
      View in: PubMed
    115. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30. PMID: 18234424.
      View in: PubMed
    116. Iversen ES, Katki HA, Chen S, Berry DA, Parmigiani G. Limited family structure and breast cancer risk. JAMA. 2007 Nov 7; 298(17):2007; author reply 2007-8. PMID: 17986693.
      View in: PubMed
    117. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer. 2008 Jan; 44(1):8-11. PMID: 17981025.
      View in: PubMed
    118. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506. PMID: 17928597.
      View in: PubMed
    119. Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA Annu Symp Proc. 2007; 995. PMID: 18694095.
      View in: PubMed
    120. Parmigiani G, Chen S, Iversen ES, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007 Oct 2; 147(7):441-50. PMID: 17909205; PMCID: PMC2423214.
    121. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704. PMID: 17704418.
      View in: PubMed
    122. Berry DA, Ravdin PM. Breast cancer trends: a marriage between clinical trial evidence and epidemiology. J Natl Cancer Inst. 2007 Aug 1; 99(15):1139-41. PMID: 17652274.
      View in: PubMed
    123. Berry DA. The difficult and ubiquitous problems of multiplicities. Pharm Stat. 2007 Jul-Sep; 6(3):155-60. PMID: 17879328.
      View in: PubMed
    124. Berry DA. Adaptive trial design. Clin Adv Hematol Oncol. 2007 Jul; 5(7):522-4. PMID: 17679925.
      View in: PubMed
    125. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics. 2007 Jun; 63(2):429-36. PMID: 17688495.
      View in: PubMed
    126. Berry D. Commentary: the hazards of survival comparisons. Oncologist. 2007 May; 12(5):510-1. PMID: 17522236.
      View in: PubMed
    127. Pujol JL, Paul S, Chouaki N, Peterson P, Moore P, Berry DA, Salzberg M. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol. 2007 May; 2(5):397-401. PMID: 17473654.
      View in: PubMed
    128. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19; 356(16):1670-4. PMID: 17442911.
      View in: PubMed
    129. Berry DA. Biomarker studies and other difficult inferential problems: statistical caveats. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S17-22. PMID: 17512432.
      View in: PubMed
    130. Lewis RJ, Lipsky AM, Berry DA. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation. Clin Trials. 2007; 4(1):5-14. PMID: 17327241.
      View in: PubMed
    131. Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer. 2006 Oct 1; 107(7):1459-66. PMID: 16948128.
      View in: PubMed
    132. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z, Broglio K, Berry DA, Hung MC. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol. 2006 Oct; 26(19):7269-82. PMID: 16980628; PMCID: PMC1592879.
    133. Berry DA. Bayesian statistics. Med Decis Making. 2006 Sep-Oct; 26(5):429-30. PMID: 16997921.
      View in: PubMed
    134. Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006 Dec; 100(3):301-8. PMID: 16773437.
      View in: PubMed
    135. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67. PMID: 16609087.
      View in: PubMed
    136. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006 Feb 20; 24(6):863-71. PMID: 16484695; PMCID: PMC2323978.
    137. Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006; (36):30-6. PMID: 17032892.
      View in: PubMed
    138. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8(6):R66. PMID: 17129383; PMCID: PMC1797029.
    139. Johnson C, Peterson SK, Turley JP, Ensor J, Amos C, Spitz M, Levin B, Berry D. Strategies to improve healthcare websites. AMIA Annu Symp Proc. 2006; 969. PMID: 17238588; PMCID: PMC1839686.
    140. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006 Jan; 5(1):27-36. PMID: 16485344.
      View in: PubMed
    141. Huang X, Biswas S, Estey EH, Berry DA. Building and validating a prognostic index for biomarker studies. Cancer Biomark. 2006; 2(3-4):97-101. PMID: 17192064.
      View in: PubMed
    142. Biswas S, Lin S, Berry DA. A new Bayesian approach incorporating covariate information for heterogeneity and its comparison with HLOD. BMC Genet. 2005; 6 Suppl 1:S138. PMID: 16451597; PMCID: PMC1866798.
    143. Paci E, Ponti A, Crocetti E, Zappa M, Segnan N. Re: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005 Dec 21; 97(24):1853-4; author reply 1854. PMID: 16368949.
      View in: PubMed
    144. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 Dec 17; 366(9503):2087-106. PMID: 16360786.
      View in: PubMed
    145. Berry D. Breast cancer heterogeneity may explain peaks in recurrence. Int J Surg. 2005; 3(4):287. PMID: 17462300.
      View in: PubMed
    146. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9. PMID: 16293864.
      View in: PubMed
    147. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005 Oct 27; 353(17):1784-92. PMID: 16251534.
      View in: PubMed
    148. Biswas S, Berry DA. Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods. Genet Epidemiol. 2005 Sep; 29(2):141-54. PMID: 16025444.
      View in: PubMed
    149. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005 Aug 17; 97(16):1195-203. PMID: 16106024.
      View in: PubMed
    150. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005 Jul 1; 23(19):4287-97. PMID: 15994142.
      View in: PubMed
    151. Berry DA. Clinical trials: is the Bayesian approach ready for prime time? Yes! Stroke. 2005 Jul; 36(7):1621-2. PMID: 15947276.
      View in: PubMed
    152. Berry DA. The Bayesian principle: can we adapt? Stroke. 2005 Jul; 36(7):1623-4. PMID: 15947273.
      View in: PubMed
    153. Jimenez C, Yang Y, Kim HW, Al-Sagier F, Berry DA, El-Naggar AK, Patel S, Vassilopoulou-Sellin R, Gagel RF. Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res. 2005 Sep; 20(9):1562-8. PMID: 16059628.
      View in: PubMed
    154. Krams M, Lees KR, Berry DA. The past is the future: innovative designs in acute stroke therapy trials. Stroke. 2005 Jun; 36(6):1341-7. PMID: 15879340.
      View in: PubMed
    155. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005 Mar 2; 293(9):1073-81. PMID: 15741529.
      View in: PubMed
    156. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1; 23(16):3676-85. PMID: 15738535.
      View in: PubMed
    157. Lipscomb B, Ma G, Berry DA. Bayesian predictions of final outcomes: regulatory approval of a spinal implant. Clin Trials. 2005; 2(4):325-33; discussion 334-9, 364-78. PMID: 16281431.
      View in: PubMed
    158. Berry DA. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin Trials. 2005; 2(4):295-300; discussion 301-4, 364-78. PMID: 16281428.
      View in: PubMed
    159. Johnson C, Ensor J, Amos C, Spitz M, Peterson S, Levin B, Berry DA. An informatics tool to assess colon cancer risk. AMIA Annu Symp Proc. 2005; 998. PMID: 16779285; PMCID: PMC1560488.
    160. Döllinger M, Tayama N, Berry DA. Empirical Eigenfunctions and medial surface dynamics of a human vocal fold. Methods Inf Med. 2005; 44(3):384-91. PMID: 16113761.
      View in: PubMed
    161. Berry DA, Wright D, Xie C, Seltzer JD, Smith JS. Using molecular sizes of simple sequence repeats vs. discrete binned data in assessing probability of ancestry: application to maize hybrids. Genetics. 2005 May; 170(1):365-74. PMID: 15466437; PMCID: PMC1449699.
    162. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 2; 351(10):971-7. PMID: 15342805.
      View in: PubMed
    163. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 1; 59(5):1337-42. PMID: 15275718.
      View in: PubMed
    164. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 1; 22(11):2061-8. PMID: 15169793.
      View in: PubMed
    165. Berry SM, Berry DA. Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics. 2004 Jun; 60(2):418-26. PMID: 15180667.
      View in: PubMed
    166. Berry D. Commentary: screening mammography: a decision analysis. Int J Epidemiol. 2004 Feb; 33(1):68; discussion 69-73. PMID: 15075148.
      View in: PubMed
    167. Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiedorek FT, Belder R. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med. 2004 Jan 12; 164(1):40-4. PMID: 14718320.
      View in: PubMed
    168. Kimmick G, Ratain MJ, Berry D, Woolf S, Norton L, Muss HB. Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs. 2004 Jan; 22(1):83-9. PMID: 14707498.
      View in: PubMed
    169. Berry DA, Seltzer JD, Xie C, Wright DL, Jones ES, Sebastian S, Smith JS. Assessing probability of ancestry using simple sequence repeat profiles: applications to maize inbred lines and soybean varieties. Genetics. 2003 Sep; 165(1):331-42. PMID: 14504240.
      View in: PubMed
    170. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003 Aug; 83(4):803-19. PMID: 12875597.
      View in: PubMed
    171. Berry DA, Berry SM, McKellar J, Pearson TA. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Am Heart J. 2003 Jun; 145(6):1036-45. PMID: 12796760.
      View in: PubMed
    172. Parnes HL, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Henderson IC, Norton L. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. J Clin Oncol. 2003 May 1; 21(9):1819-24. PMID: 12721259.
      View in: PubMed
    173. Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 2003 May 1; 21(9):1825-35. PMID: 12721260.
      View in: PubMed
    174. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003 May 1; 21(9):1722-7. PMID: 12721247.
      View in: PubMed
    175. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83. PMID: 12637460.
      View in: PubMed
    176. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9. PMID: 12668651.
      View in: PubMed
    177. Berry DA. General keynote: clinical trial design. Gynecol Oncol. 2003 Jan; 88(1 Pt 2):S114-6; S122-3. PMID: 12586099.
      View in: PubMed
    178. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002 Dec; 58(4):823-31. PMID: 12495136.
      View in: PubMed
    179. Cremin C, Wong N, Buzaglo K, Paradis AJ, Foulkes W. Nonovarian pelvic cancers in BRCA1/2 mutation carriers and the BRCAPRO statistical model. J Clin Oncol. 2002 Sep 15; 20(18):3936; author reply 3936-7. PMID: 12228218.
      View in: PubMed
    180. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002 Sep 1; 20(17):3628-36. PMID: 12202663.
      View in: PubMed
    181. Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 1; 20(11):2701-12. PMID: 12039933.
      View in: PubMed
    182. Berry DA, Seltzer JD, Xie C, Wright DL, Smith JS. Assessing probability of ancestry using simple sequence repeat profiles: applications to maize hybrids and inbreds. Genetics. 2002 Jun; 161(2):813-24. PMID: 12072476; PMCID: PMC1462128.
    183. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9. PMID: 12006521.
      View in: PubMed
    184. Petros WP, Broadwater G, Berry D, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP, Colvin OM, Peters WP. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res. 2002 Mar; 8(3):698-705. PMID: 11895898.
      View in: PubMed
    185. Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, Budman DR, Henderson IC, Norton L, Hayes DF. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. J Clin Oncol. 2002 Feb 1; 20(3):732-42. PMID: 11821455.
      View in: PubMed
    186. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002 Feb 1; 20(3):743-50. PMID: 11821456.
      View in: PubMed
    187. Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test. 2002; 6(2):93-105. PMID: 12215248.
      View in: PubMed
    188. Lewis RJ, Berry DA, Cryer H, Fost N, Krome R, Washington GR, Houghton J, Blue JW, Bechhofer R, Cook T, Fisher M. Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent: the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial. Ann Emerg Med. 2001 Oct; 38(4):397-404. PMID: 11574796.
      View in: PubMed
    189. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res. 2001 Sep; 7(9):2703-11. PMID: 11555582.
      View in: PubMed
    190. Berry DA. Role of population-based studies in assessing genetic cancer risk. J Natl Cancer Inst. 2001 Aug 15; 93(16):1188-9. PMID: 11504754.
      View in: PubMed
    191. Zhang W, Labordé PM, Coombes KR, Berry DA, Hamilton SR. Cancer genomics: promises and complexities. Clin Cancer Res. 2001 Aug; 7(8):2159-67. PMID: 11489789.
      View in: PubMed
    192. Pecora AL, Lazarus HM, Stadtmauer EA, Winter J, Van Vliet A, Berry D, Gray R, Jennis A, Goldberg S, Cooper BW, Preti R. Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer. Bone Marrow Transplant. 2001 Jun; 27(12):1245-53. PMID: 11548842.
      View in: PubMed
    193. Berry DA, Clark MJ, Montequin DW, Titze IR. Characterization of the medial surface of the vocal folds. Ann Otol Rhinol Laryngol. 2001 May; 110(5 Pt 1):470-7. PMID: 11372933.
      View in: PubMed
    194. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, Rizzeri D, Vredenburgh JJ, Bentley RC. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 2001 Mar 15; 19(6):1698-706. PMID: 11250999.
      View in: PubMed
    195. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000 Oct 15; 18(20):3471-9. PMID: 11032587.
      View in: PubMed
    196. Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst. 2000 Mar 15; 92(6):486-92. PMID: 10716967.
      View in: PubMed
    197. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000 Feb; 18(3):600-8. PMID: 10653875.
      View in: PubMed
    198. Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol. 1999 Oct; 17(10):3064-74. PMID: 10506601.
      View in: PubMed
    199. Hryniuk W. Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1425. PMID: 10451457.
      View in: PubMed
    200. Ashih H, Gustilo-Ashby T, Myers ER, Andrews J, Clarke-Pearson DL, Berry D, Berchuck A. Cost-effectiveness of treatment of early stage endometrial cancer. Gynecol Oncol. 1999 Aug; 74(2):208-16. PMID: 10419733.
      View in: PubMed
    201. Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol. 1999 May; 17(5):1465-73. PMID: 10334532.
      View in: PubMed
    202. Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406. PMID: 10334524.
      View in: PubMed
    203. Berry DA, Moon JB, Kuehn DP. A finite element model of the soft palate. Cleft Palate Craniofac J. 1999 May; 36(3):217-23. PMID: 10342609.
      View in: PubMed
    204. Cameron DA, Leonard RC. Re: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1999 Apr 21; 91(8):728-9. PMID: 10218517.
      View in: PubMed
    205. Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol. 1999 Mar; 17(3):1040-6. PMID: 10071299.
      View in: PubMed
    206. Kopans DB, Halpern E. Re: Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst. 1999 Feb 17; 91(4):382-4. PMID: 10050875.
      View in: PubMed
    207. Vollmer RT. Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1999 Feb 3; 91(3):286-7. PMID: 10037109.
      View in: PubMed
    208. Abrams J, Aisner J, Cirrincione C, Berry DA, Muss HB, Cooper MR, Henderson IC, Panasci L, Kirshner J, Ellerton J, Norton L. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol. 1999 Jan; 17(1):64-73. PMID: 10458219.
      View in: PubMed
    209. Claus EB, Schildkraut J, Iversen ES, Berry D, Parmigiani G. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst. 1998 Dec 2; 90(23):1824-9. PMID: 9839523.
      View in: PubMed
    210. Berry DA. Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst. 1998 Oct 7; 90(19):1431-9. PMID: 9776408.
      View in: PubMed
    211. Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making. 1998 Oct-Dec; 18(4):365-75. PMID: 10372578.
      View in: PubMed
    212. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998 Sep 16; 90(18):1346-60. PMID: 9747866.
      View in: PubMed
    213. Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ. Overestimation of hereditary breast cancer risk. Ann Surg. 1998 Sep; 228(3):375-84. PMID: 9742920.
      View in: PubMed
    214. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998 Aug 19; 90(16):1205-11. PMID: 9719081.
      View in: PubMed
    215. Berry DA. Screening mammography for women in their forties. Breast Dis. 1998 Aug; 10(3-4):23-32. PMID: 15687561.
      View in: PubMed
    216. Berry DA, Parmigiani G. Assessing the benefits of testing for breast cancer susceptibility genes: a decision analysis. Breast Dis. 1998 Apr; 10(1-2):115-25. PMID: 15687554.
      View in: PubMed
    217. Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, LeGrand S, Peters WP, Vredenburgh JJ. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol. 1998 Mar; 16(3):1008-12. PMID: 9508184.
      View in: PubMed
    218. Fisher DC, Vredenburgh JJ, Petros WP, Hussein A, Berry DA, Elkordy M, Rubin P, Gilbert CJ, Peters WP. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant. 1998 Jan; 21(2):117-22. PMID: 9489626.
      View in: PubMed
    219. Gilbert CJ, Petros WP, Vredenburgh J, Hussein A, Ross M, Rubin P, Fehdrau R, Cavanaugh C, Berry D, McKinstry C, Peters WP. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol. 1998; 42(6):497-503. PMID: 9788577.
      View in: PubMed
    220. Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer. 1998; 77(1):51-6. PMID: 9459145.
      View in: PubMed
    221. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998 Jan; 62(1):145-58. PMID: 9443863; PMCID: PMC1376797.
    222. Cooper DA, Berry DA, Spendel VA, Jones MB, Kiorpes AL, Peters JC. Nutritional status of pigs fed olestra with and without increased dietary levels of vitamins A and E in long-term studies. J Nutr. 1997 Aug; 127(8 Suppl):1609S-1635S. PMID: 9237959.
      View in: PubMed
    223. Cooper DA, Berry DA, Spendel VA, Kiorpes AL, Peters JC. The domestic pig as a model for evaluating olestra's nutritional effects. J Nutr. 1997 Aug; 127(8 Suppl):1555S-1565S. PMID: 9237954.
      View in: PubMed
    224. Cooper DA, Berry DA, Spendel VA, King D, Kiorpes AL, Peters JC. Olestra dose response on fat-soluble and water-soluble nutrients in the pig. J Nutr. 1997 Aug; 127(8 Suppl):1573S-1588S. PMID: 9237956.
      View in: PubMed
    225. Cooper DA, Berry DA, Jones MB, Kiorpes AL, Peters JC. Olestra's effect on the status of vitamins A, D and E in the pig can be offset by increasing dietary levels of these vitamins. J Nutr. 1997 Aug; 127(8 Suppl):1589S-1608S. PMID: 9237957.
      View in: PubMed
    226. Vredenburgh JJ, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, Petros WP, Peters WP, Bast RC. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant. 1997 Jun; 3(2):91-7. PMID: 9267669.
      View in: PubMed
    227. Alpert LC, Schecter RL, Berry DA, Melnychuk D, Peters WP, Caruso JA, Townsend AJ, Batist G. Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Clin Cancer Res. 1997 May; 3(5):661-7. PMID: 9815734.
      View in: PubMed
    228. Roach M, Cirrincione C, Budman D, Hayes D, Berry D, Younger J, Hart R, Henderson IC. Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am. 1997 Mar-Apr; 3(2):107-12. PMID: 9099461.
      View in: PubMed
    229. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997 Feb 5; 89(3):227-38. PMID: 9017003.
      View in: PubMed
    230. Berry DA. When is a confirmatory randomized clinical trial needed? J Natl Cancer Inst. 1996 Nov 20; 88(22):1606-7. PMID: 8931598.
      View in: PubMed
    231. Hussein AM, Petros WP, Ross M, Vredenburgh JJ, Affrontil ML, Jones RB, Shpall EJ, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin MJ, Soper J, Berchuck A, Clarke-Person D, Berry DA, Peters WP. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol. 1996; 37(6):561-8. PMID: 8612310.
      View in: PubMed
    232. Kute TE, Quadri Y, Muss H, Zbieranski N, Cirrincione C, Berry DA, Barcos M, Thor AP, Liu E, Koerner F, et al. Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869. Cytometry. 1995 Dec 15; 22(4):297-306. PMID: 8749780.
      View in: PubMed
    233. Costanza ME, Berry D, Henderson IC, Ratain MJ, Wu K, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss AP. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704. PMID: 9816035.
      View in: PubMed
    234. Rosner GL, Berry DA. A Bayesian group sequential design for a multiple arm randomized clinical trial. Stat Med. 1995 Feb 28; 14(4):381-94. PMID: 7746978.
      View in: PubMed
    235. Berry DA, Eick SG. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med. 1995 Feb 15; 14(3):231-46. PMID: 7724909.
      View in: PubMed
    236. Berry DA. Decision analysis and Bayesian methods in clinical trials. Cancer Treat Res. 1995; 75:125-54. PMID: 7640161.
      View in: PubMed
    237. Perry JJ, Berry DA, Weiss RB, Hayes DM, Duggan DB, Henderson IC. High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB). Breast Cancer Res Treat. 1995; 36(1):35-40. PMID: 7579504.
      View in: PubMed
    238. Berry DA, Wolff MC, Sack D. Decision making during a phase III randomized controlled trial. Control Clin Trials. 1994 Oct; 15(5):360-78. PMID: 8001357.
      View in: PubMed
    239. George SL, Li C, Berry DA, Green MR. Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. Stat Med. 1994 Jul 15-30; 13(13-14):1313-27. PMID: 7973212.
      View in: PubMed
    240. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 5; 330(18):1260-6. PMID: 7908410.
      View in: PubMed
    241. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Iglehart JD. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994 Apr; 219(4):332-41. PMID: 7909221.
      View in: PubMed
    242. Berry DA. Clinical research in the critical care environment. Crit Care Med. 1993 Sep; 21(9 Suppl):S400-2. PMID: 8365257.
      View in: PubMed
    243. Berry DA. A case for Bayesianism in clinical trials. Stat Med. 1993 Aug; 12(15-16):1377-93; discussion 1395-404. PMID: 8248653.
      View in: PubMed
    244. Berry DA. Power of chronobiologic pilots: a statistician's opinion. Chronobiologia. 1993 Jul-Dec; 20(3-4):213-8. PMID: 8131670.
      View in: PubMed
    245. Berry DA. Transparent polyurethane film as a catheter dressing. JAMA. 1992 Nov 11; 268(18):2514-5. PMID: 1404814.
      View in: PubMed
    246. Robertson SE, Markowitz LE, Berry DA, Dini EF, Orenstein WA. A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy. Public Health Rep. 1992 Jan-Feb; 107(1):24-31. PMID: 1738804.
      View in: PubMed
    247. Berry DA. Experimental design for drug development: a Bayesian approach. J Biopharm Stat. 1991; 1(1):81-101. PMID: 1844693.
      View in: PubMed
    248. Berry DA. Subgroup analyses. Biometrics. 1990 Dec; 46(4):1227-30. PMID: 2085637.
      View in: PubMed
    249. Salerno DM, Gillingham KJ, Berry DA, Hodges M. A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: a meta-analysis. Am Heart J. 1990 Aug; 120(2):340-53. PMID: 1696426.
      View in: PubMed
    250. Hillman D, Fernández JR, Cornélissen G, Berry DA, Halberg J, Halberg F. Bounded limits and statistical inference in chronobiometry. Prog Clin Biol Res. 1990; 341B:417-28. PMID: 2217334.
      View in: PubMed
    251. Berry DA. Monitoring accumulating data in a clinical trial. Biometrics. 1989 Dec; 45(4):1197-211. PMID: 2611322.
      View in: PubMed
    252. Holtzman JL, Weeks CE, Kvam DC, Berry DA, Mottonen L, Ekholm BP, Chang SF, Conard GJ. Identification of drug interactions by meta-analysis of premarketing trials: the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetate. Clin Pharmacol Ther. 1989 Jul; 46(1):1-8. PMID: 2501055.
      View in: PubMed
    253. Holtzman JL, Finley D, Mottonen L, Berry DA, Ekholm BP, Kvam DC, McQuinn RL, Miller AM. The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. Clin Pharmacol Ther. 1989 Jul; 46(1):26-32. PMID: 2501057.
      View in: PubMed
    254. Van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J. Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk. A Pediatric Oncology Group Study. Cancer. 1989 Apr 15; 63(8):1466-71. PMID: 2924255.
      View in: PubMed
    255. van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J, Wharam M. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study. Cancer. 1989 Jan 1; 63(1):23-9. PMID: 2910421.
      View in: PubMed
    256. Gitter MJ, Salerno DM, Berry DA, Fifield JH, Farmer CK. Variability of different methods for measurement of ECG intervals and ECG interval temporal variation. J Electrocardiol. 1989; 22 Suppl:125-6. PMID: 2614290.
      View in: PubMed
    257. Berry DA, Ho CH. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Biometrics. 1988 Mar; 44(1):219-27. PMID: 3358990.
      View in: PubMed
    258. Berry DA. Logarithmic transformations in ANOVA. Biometrics. 1987 Jun; 43(2):439-56. PMID: 3300800.
      View in: PubMed
    259. Holtzman JL, Kvam DC, Berry DA, Mottonen L, Borrell G, Harrison LI, Conard GJ. The pharmacodynamic and pharmacokinetic interaction of flecainide acetate with propranolol: effects on cardiac function and drug clearance. Eur J Clin Pharmacol. 1987; 33(1):97-9. PMID: 3121353.
      View in: PubMed
    260. Berry DA. Interim analyses in clinical research. Cancer Invest. 1987; 5(5):469-77. PMID: 3427509.
      View in: PubMed
    261. Holtzman JL, Finley D, Johnson B, Berry DA, Sirgo MA. The effects of single-dose atenolol, labetalol, and propranolol on cardiac and vascular function. Clin Pharmacol Ther. 1986 Sep; 40(3):268-73. PMID: 3742933.
      View in: PubMed
    262. Salerno DM, Granrud G, Sharkey P, Krejci J, Larson T, Erlien D, Berry D, Hodges M. Pharmacodynamics and side effects of flecainide acetate. Clin Pharmacol Ther. 1986 Jul; 40(1):101-7. PMID: 3720173.
      View in: PubMed
    263. Berry DA, Pearson LM. Optimal designs for clinical trials with dichotomous responses. Stat Med. 1985 Oct-Dec; 4(4):497-508. PMID: 4089351.
      View in: PubMed
    264. Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med. 1985 Oct-Dec; 4(4):521-6. PMID: 4089353.
      View in: PubMed
    265. Berry DA, Eaton ML, Ekholm BP, Fox TL. Assessing differential drug effect. Biometrics. 1984 Dec; 40(4):1109-15. PMID: 6398711.
      View in: PubMed
    266. Holtzman JL, Berry DA, Kvam DC, Mottonen L, Borrell G. Application of second-order polynomial equations to the study of pharmacodynamic interactions: the effect of flecainide acetate and propranolol on cardiac output and vascular resistance. J Pharmacol Exp Ther. 1984 Nov; 231(2):286-90. PMID: 6491982.
      View in: PubMed
    267. Berry DA, Fox TL. Regression analysis applied to PVC histories: a statistical procedure for evaluating antiarrhythmic drug efficacy. Stat Med. 1983 Jul-Sep; 2(3):331-43. PMID: 6359320.
      View in: PubMed
    268. Berry DA. Statistical inference and the design of clinical trials. Biomedicine. 1980 Feb; 32(1):4-7. PMID: 7370380.
      View in: PubMed
    269. The neoadjuvant model is still the future for drug development in breast cancer. Clinical Cancer Research. 21:2911-2915.
    270. Comment. Statistical Science. 4:306-310.
    271. Herceptin plus chemotherapy combination in preoperative regimen may offer clinical benefit in early stage breast cancer. Cancer Biology and Therapy. 4.
    272. Reply. Clinical Trials. 6:394.
    273. Bayesian methods in phase III trials. Therapeutic Innovation and Regulatory Science. 25:345-368.
    274. In reply. Journal of Clinical Oncology. 21:4465-4466.
    275. Modified two-armed bandit strategies for certain clinical trials. Journal of the American Statistical Association. 73:339-345.
    276. Probabilities of winning a certain carnival game. American Statistician. 32:126-129.
    277. DISCRETE SEARCH WITH DIRECTIONAL INFORMATION. Operations Research. 34:470-477.
    278. Bandit problems with infinitely many arms. Annals of Statistics. 25:2103-2116.
    279. Choosing sample size for a clinical trial using decision analysis. Biometrika. 90:923-936.
    280. Biostatistics and Bioinformatics in Clinical Trials. 282-293.
    281. Bayesian model averaging in meta-analysis. Clinical Trials. 6:50-51.
    282. The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Disease Management and Clinical Outcomes. 2:15-24.
    283. Bayesian multiple comparisons using dirichlet process priors. Journal of the American Statistical Association. 93:1130-1139.
    284. Efficient dose-response finding strategies for acute neuroemergency treatments. 179-204.
    285. Relationship between bayesian and frequentist sample size determination. American Statistician. 59:79-87.
    286. Optimal adaptive randomized designs for clinical trials. Biometrika. 94:673-687.
    287. Reply to M. Moroni and U. De Giorgi et al. Journal of Clinical Oncology. 30:759-760.
    288. Genetic Susceptibility and Survival. Journal of the American Statistical Association. 95:28-42.
    289. Drs. Berry and Esserman reply. New England Journal of Medicine. 375:1592-1593.
    290. The Brave New World of clinical cancer research. Molecular Oncology. 9:951-959.
    291. Genetic diversity among U.S. sunflower inbreds and hybrids. Crop Science. 49:1295-1303.
    292. Bayesian perspectives on multiple comparisons. Journal of Statistical Planning and Inference. 82:215-227.
    293. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal. 43:539-556.
    294. Floor discussion. Clinical Trials. 2:301-304.
    295. Bayesian methods in Phase III trials. Drug Information Journal. 25:345-368.
    296. Journal of the American Statistical Association. 69:485-491.
    297. Breast cancer heterogeneity may explain peaks in recurrence [2]. International Journal of Surgery. 3:287.
    298. Discussion of "multivariate bayesian logistic regression for analysis of clinical trial safety issues" by w. Dumouchel. Statistical Science. 27:344-345.
    299. In reply [12]. Journal of Clinical Oncology. 23:6804-6805.
    300. An improved procedure for selecting the better of two bernoulli populations. Journal of the American Statistical Association. 68:979-984.
    301. Bayesian Survival Analysis With Nonproportional Hazards Metanalysis of Combination Pravastatin-Aspirin. Journal of the American Statistical Association. 99:36-44.
    302. A response-adaptive design of initial therapy for emergency department patients with heart failure. Contemporary Clinical Trials. 52:46-53.
    303. Comment. Statistical Science. 9:253-255.
    304. The authors reply. New England Journal of Medicine. 361:1023-1024.
    305. Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development. Therapeutic Innovation and Regulatory Science. 43:539-556.
    306. Symmetrized percent change for treatment comparisons. American Statistician. 60:27-31.
    307. The authors reply [13]. New England Journal of Medicine. 358:198.
    308. Breast Cancer Research and Treatment. 160:297-304.
    309. Letters to the editor. American Statistician. 26:47.
    310. Attitudes and opinions regarding confirmatory adaptive clinical trials. Trials. 17.
    311. Screening mammography for women in their forties. Breast Disease. 10:23-32.
    312. The probability of a field goal. American Statistician. 39:152-155.
    313. Teaching Elementary Bayesian Statistics with Real Applications in Science. American Statistician. 51:241-246.
    314. Interim analysis in clinical trials; the role of the likelihood principle. American Statistician. 41:117-122.
    315. Maximizing the length of a success run for many-armed bandits. Stochastic Processes and their Applications. 15:317-325.
    316. Rejoinder. Statistical Science. 6:202-205.
    317. CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro-Oncology. 17:vi1-vi26.
    318. The authors reply [13]. New England Journal of Medicine. 354:769.
    319. Erratum. Clinical Pharmacology and Therapeutics. 48:224.
    320. Advancing clinical trials to streamline drug development. Clinical Cancer Research. 21:4527-4535.
    321. Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules. Annals of Internal Medicine. 152:136.
    322. Breast Cancer. 47-61.
    323. In reply [14]. Journal of Clinical Oncology. 23:8131-8132.
    324. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2:1-12.
    325. Clinical trialist perspectives on the ethics of adaptive clinical trials. BMC Medical Ethics. 16.
    326. Simulation-based sequential Bayesian design. Journal of Statistical Planning and Inference. 137:3140-3150.
    327. In reply [8]. Journal of Clinical Oncology. 25:2634-2635.
    328. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Research and Treatment. 161:363-373.
    329. Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Science. 19:175-187.
    330. Bernoulli two-armed bandits with geometric termination. Stochastic Processes and their Applications. 11:35-45.
    331. Group sequential clinical trials. Journal of the American Statistical Association. 89:1528-1534.
    332. Interpreting adjuvant breast cancer data in 2006 and beyond. European Journal of Cancer, Supplement. 4:17-22.
    333. Regional Changes in Hormone Therapy Use and Breast Cancer Incidence in California From 2001 to 2004. Breast Diseases. 19:131-132.
    334. Adaptive dose-response studies. Drug Information Journal. 40:451-461.
    335. Comment. American Statistician. 68:88-89.
    336. Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process-Findings from a qualitative study. Clinical Research and Regulatory Affairs. 32:121-130.
    337. A class of optimal stopping problems for sampling without replacement. Biometrika. 61:361-368.
    338. Inferences using DNA profiling in forensic identification and paternity cases. Statistical Science. 6:175-189.
    339. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro-Oncology. 17:1106-1113.
    340. FDA recalls not as alarming as they seem. Archives of Internal Medicine. 171:1004-1005.
    341. Right-sizing adjuvant and neoadjuvant clinical trials in breast cancer. Clinical Cancer Research. 22:3-5.
    342. Accelerated approval of promising agents in the neoadjuvant setting. Breast Diseases. 24:126-128.
    BERRY's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description